This site uses cookies. By using this site you agree to receiving cookies. View Policy.

145%

TC BioPharm is a world-leading immunotherapy company that has seen positive results in its latest clinical cancer trial. They are now looking to advance those trials as well as extend their IP protected technology to a COVID-19 therapy, having recently received regulatory approval for a Phase I trial.

  • Encouraging results in our latest cancer trial
  • Immunotherapy leader with over £38m raised in funding to date
  • Validation from partnerships with two global pharmaceutical companies
  • EIS eligible shares with down-round protection and min 1.5x on exit
Information TC BioPharm has previously raised £3.42m on the same terms as those available as part of this pitch. The company has not spent £1.2m of these funds at the date the pitch went live, and this is reflected on the progress bar for clarity. Some of these funds may be spent while the campaign is live.

Idea

Immunotherapy is one of the most important innovations in healthcare to emerge in the last 20 years. It is a form of treatment that uses the body's own immune system to prevent cancer and infectious disease. Using patented technology, TC BioPharm harnesses the power of a particular part of the immune system, gamma delta T-cells (GDT), with encouraging results.

Cancer trial success

We have treated terminally ill patients with acute myeloid leukaemia in approved clinical trials. Initial results are very encouraging and with positive responses in multiple patients. There were no material side effects.

Commercial opportunity

Immunotherapies are, in many cases, very expensive treatments. Using our GDT technology could enable us to provide a much lower cost solution, making it more widely accessible to patients.

Next steps

Supported by recent clinical evidence, we are delighted to have received regulatory approval from the MHRA to run a COVID-19 clinical trial to address the global pandemic. In addition, we will advance our current technology to provide a frozen product that can be manufactured cost-effectively and distributed globally.

Series A funding round

We have already raised over £7m in the last 15 months and are seeking to raise additional investment to take our clinical trials forward in COVID-19 and cancer.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the TC BioPharm Limited pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered?
Log in

Risk warning

Investments of this nature carry risks to your capital, including illiquidity, lack of dividends and dilution. Balance risk with a diversified portfolio. Read more. Approved as a financial promotion by Crowdcube Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

TC BioPharm Limited has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Enterprise Investment Scheme (EIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 30 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.